ATE258797T1 - Verwendung von amifostin - Google Patents

Verwendung von amifostin

Info

Publication number: ATE258797T1
Authority: AT; Austria
Prior art keywords: compounds; aminoalkyl; amifostine; adverse; patients
Prior art date: 1997-02-12

Application number

AT98906688T

Other languages

English (en)

Inventor

Martin Stogniew

Philip S Schein

Original Assignee

Medimmune Oncology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-12

Filing date

1998-02-11

Publication date

2004-02-15

1998-02-11 Application filed by Medimmune Oncology Inc filed Critical Medimmune Oncology Inc

2004-02-15 Application granted granted Critical

2004-02-15 Publication of ATE258797T1 publication Critical patent/ATE258797T1/de

Links

JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 title 1
229960001097 amifostine Drugs 0.000 title 1
-1 aminoalkyl phosphorothioate Chemical compound 0.000 abstract 2
230000002411 adverse Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000007423 decrease Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Insulating Materials (AREA)

AT98906688T 1997-02-12 1998-02-11 Verwendung von amifostin ATE258797T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/798,840 US6051563A (en)	1997-02-12	1997-02-12	Methods for the administration of amifostine and related compounds
PCT/US1998/003614 WO1998034622A1 (en)	1997-02-12	1998-02-11	Methods for the administration of amifostine

Publications (1)

Publication Number	Publication Date
ATE258797T1 true ATE258797T1 (de)	2004-02-15

Family

ID=25174410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98906688T ATE258797T1 (de)	1997-02-12	1998-02-11	Verwendung von amifostin

Country Status (11)

Country	Link
US (3)	US6051563A (de)
EP (1)	EP1007055B1 (de)
JP (1)	JP2001512447A (de)
AT (1)	ATE258797T1 (de)
AU (1)	AU750591B2 (de)
CA (2)	CA2280773C (de)
DE (1)	DE69821498T2 (de)
DK (1)	DK1007055T3 (de)
ES (1)	ES2216271T3 (de)
PT (1)	PT1007055E (de)
WO (1)	WO1998034622A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6753006B1 (en)	1993-02-22	2004-06-22	American Bioscience, Inc.	Paclitaxel-containing formulations
US6051563A (en) *	1997-02-12	2000-04-18	U.S. Bioscience, Inc.	Methods for the administration of amifostine and related compounds
US6573253B2 (en) *	1997-02-12	2003-06-03	Medimmune Oncology Inc.	Methods for the administration of amifostine and related compounds
US5994409A (en) *	1997-12-09	1999-11-30	U.S. Bioscience, Inc.	Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) *	1998-04-27	2001-05-29	Medimmune Oncology, Inc.	Topical administration of amifostine and related compounds
US6384259B1 (en) *	1998-11-16	2002-05-07	Medimmune Oncology, Inc.	Stable amorphous amifostine compositions and dosage form
US6407278B2 (en)	1998-11-16	2002-06-18	Medimmune Oncology, Inc.	Stable amorphous amifostine compositions and methods for the preparation and use of the same
WO2001080832A2 (en) *	2000-04-26	2001-11-01	Oregon Health Sciences University	Administration of a thiol-based chemoprotectant compound
US7053072B2 (en) *	2001-05-11	2006-05-30	Medimmune Oncology, Inc.	Methods for the administration of amifostine and related compounds
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
ATE343376T1 (de) *	2002-03-20	2006-11-15	Elan Pharma Int Ltd	Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US20080220075A1 (en) *	2002-03-20	2008-09-11	Elan Pharma International Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
US7629333B2 (en)	2002-03-29	2009-12-08	Medimmune, Llc	Stable amorphous amifostine compositions and methods for the preparation and use of same
WO2006044738A2 (en) *	2004-10-18	2006-04-27	Maroon Biotech Corporation	Methods and compositions for treatment of free radical injury
PT2453910T (pt)	2009-07-15	2016-12-07	Portola Pharm Inc	Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
CN103336902B (zh) *	2013-06-27	2016-01-13	西安交通大学	一种基于模拟分布平衡血药浓度的药物绝对生物利用度检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3892824A (en) *	1968-12-16	1975-07-01	Southern Res Inst	S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
AU636107B2 (en) *	1988-02-23	1993-04-22	U.S. Bioscience, Inc.	Method for protection from chemotherapeutic side effects
US5424471A (en) *	1992-07-31	1995-06-13	U.S. Bioscience, Inc.	Crystalline amifostine compositions and methods of the preparation and use of same
SG47101A1 (en)	1992-07-31	1998-03-20	Us Bioscience	Crystalline amifostine compositions and methods for the preparation and use of same
WO1994005299A1 (fr) *	1992-09-04	1994-03-17	Fuji Kagaku Kogyo Kabushiki Kaisha	Compositions medicinales
DE69526395D1 (de) *	1994-08-13	2002-05-23	Roche Diagnostics Gmbh	Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen
US5846958A (en) *	1995-02-17	1998-12-08	U.S. Bioscience, Inc.	Methods of using aminothiols to promote hematopoietic progenitor cell growth
US6051563A (en) *	1997-02-12	2000-04-18	U.S. Bioscience, Inc.	Methods for the administration of amifostine and related compounds

1997
- 1997-02-12 US US08/798,840 patent/US6051563A/en not_active Expired - Lifetime
1998
- 1998-02-10 US US09/021,139 patent/US6127351A/en not_active Expired - Lifetime
- 1998-02-11 AT AT98906688T patent/ATE258797T1/de active
- 1998-02-11 ES ES98906688T patent/ES2216271T3/es not_active Expired - Lifetime
- 1998-02-11 PT PT98906688T patent/PT1007055E/pt unknown
- 1998-02-11 JP JP53511398A patent/JP2001512447A/ja active Pending
- 1998-02-11 WO PCT/US1998/003614 patent/WO1998034622A1/en not_active Ceased
- 1998-02-11 DE DE69821498T patent/DE69821498T2/de not_active Expired - Lifetime
- 1998-02-11 AU AU61849/98A patent/AU750591B2/en not_active Expired
- 1998-02-11 CA CA002280773A patent/CA2280773C/en not_active Expired - Fee Related
- 1998-02-11 DK DK98906688T patent/DK1007055T3/da active
- 1998-02-11 CA CA002625727A patent/CA2625727A1/en not_active Abandoned
- 1998-02-11 EP EP98906688A patent/EP1007055B1/de not_active Expired - Lifetime
2000
- 2000-06-05 US US09/586,753 patent/US6218377B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US6051563A (en)	2000-04-18
DE69821498D1 (de)	2004-03-11
DE69821498T2 (de)	2004-12-02
JP2001512447A (ja)	2001-08-21
CA2625727A1 (en)	1998-08-13
CA2280773A1 (en)	1998-08-13
EP1007055B1 (de)	2004-02-04
US6218377B1 (en)	2001-04-17
EP1007055A1 (de)	2000-06-14
PT1007055E (pt)	2004-06-30
EP1007055A4 (de)	2002-05-29
WO1998034622A1 (en)	1998-08-13
CA2280773C (en)	2008-07-22
ES2216271T3 (es)	2004-10-16
AU750591B2 (en)	2002-07-25
DK1007055T3 (da)	2004-06-07
AU6184998A (en)	1998-08-26
US6127351A (en)	2000-10-03

Legal Events

Date

Code

Title

Description

2004-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1007055

Country of ref document: EP

Publication	Publication Date	Title
ATE258797T1 (de)	2004-02-15	Verwendung von amifostin
KR900009079A (ko)	1990-07-02	비스(3,5-디-tert-부틸-4-히드록시페닐티오)메탄 함유 콜레스테롤 저하제겸 아테롬성 동맥 경화증 치료제
ATE239474T1 (de)	2003-05-15	Verwendung von levobupivacain
NO20014415L (no)	2001-11-12	Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
DE69834658D1 (de)	2006-06-29	Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
MXPA03003960A (es)	2004-09-10	Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
DE69941586D1 (de)	2009-12-03	Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen
SE9702860D0 (sv)	1997-08-05	New use
PT996460E (pt)	2005-04-29	Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6
DE69617729D1 (de)	2002-01-17	Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
ATE372774T1 (de)	2007-09-15	Medikament zur verabreichung von amifostin und verwandten wirkstoffen
TR200001288T2 (tr)	2000-09-21	Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
BR9809678A (pt)	2000-07-11	Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE225177T1 (de)	2002-10-15	Verwendung von (+)mefloquine zur behandlung von malaria
FI911788A0 (fi)	1991-04-12	Konjugater av difluorglutaminsyra med folater och antifolater foer behandling av neoplastiska sjukdomar.
DE69018099D1 (de)	1995-05-04	Polyamin-Derivate als antineoplastische Mittel.
PL334093A1 (en)	2000-01-31	Application of comt inhibitors in production of drugs preventing occurence of vascular disorders in case of diabetes
MD1140B1 (en)	1999-01-31	Remedy possessing a regenerative and cytoprotective activity
BR9909867A (pt)	2000-12-19	Composições estáveis contendo levosimendan e ácido algìnico
DE60006284D1 (de)	2003-12-04	Arzneimittel zur behandlung konvulsivischer zustände
SE9003181D0 (sv)	1990-10-04	Use of heparin fraction
TR200000728T2 (tr)	2000-09-21	Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
DK0458537T3 (da)	1999-10-18	Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
ATE72115T1 (de)	1992-02-15	Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
AU2444695A (en)	1995-12-21	Use of intravenously administered iron in the therapy of tumoral and infectious diseases